TORONTO, Canada I March 4, 2016 I Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2 trial. Antibe submitted an application to Health Canada to perform a trial in which ATB-346, its lead drug, would be tested for effectiveness in patients with osteoarthritis of the knee. The study is expected to begin in March, and will be performed by Topstone Research, in Toronto. Antibe’s CEO, Daniel Legault, commented “We are delighted to move forward into patients. In the past year we have performed a number of non-clinical studies of this drug and these studies suggest that ATB-346 is a much more potent and long-lasting anti-inflammatory drug than we had anticipated.”
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
SOURCE: Antibe Therapeutics
Post Views: 126
TORONTO, Canada I March 4, 2016 I Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2 trial. Antibe submitted an application to Health Canada to perform a trial in which ATB-346, its lead drug, would be tested for effectiveness in patients with osteoarthritis of the knee. The study is expected to begin in March, and will be performed by Topstone Research, in Toronto. Antibe’s CEO, Daniel Legault, commented “We are delighted to move forward into patients. In the past year we have performed a number of non-clinical studies of this drug and these studies suggest that ATB-346 is a much more potent and long-lasting anti-inflammatory drug than we had anticipated.”
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
SOURCE: Antibe Therapeutics
Post Views: 126
